|
Post by kc on Jun 5, 2017 21:03:46 GMT -5
If they had three or four children, perhaps we could shoot for an Appel a Day? Look the woman surely is the brains of this family, why do people assume we got the rotten Appel? Plus everyone knows a woman will work cheaper than a man, or at least be forced to! I was going to say splitting the Appel but that might mean a divorce
|
|
|
Post by kc on Jun 5, 2017 21:02:48 GMT -5
I remember now mango, thanks. paraphrasing, "a simulation of sorts" not sure I choose the correct word there. thanks Computer simulation / modeling is what MannKind had said back in 2016 giving and getting faster trial data. It was in a call April or may 2016
|
|
|
Post by kc on Jun 5, 2017 20:56:06 GMT -5
Published just in time to release during ADA later this week. TickTock.
|
|
|
Post by kc on Jun 5, 2017 15:51:47 GMT -5
She has a good background if she is Jay's Wife. But Jay moved to NJ and she is still in CA? Possibly not related.
Sr. Manager Global Content Strategy
Company Name Medtronic
Dates Employed Aug 2015 – Jul 2016
Employment Duration •1 yr
Location Greater Los Angeles Area Support global content development and syndication initiatives across multiple platforms and formats * Create and execute a content development strategy * Establish processes for creating content - original editorials, approvals through to publishing and analytics * Network internally to research topics and identify subject matter experts * Create strategic and technical opportunities for content to be adopted and localized by other Diabetes regions * Establish content syndication strategy through owned, earned and paid channels * Ensure all content communicates Medtronic's mission to transform healthcare and inspires people to know us better
Support global migration of multiple regional Diabetes websites onto new Adobe (AEM) platform * Align with stakeholders * Advocate for the best user experience * Document requirements * Steward the migration of content
Support the company's advocacy mission in managing alliances and fundraising programs with American Diabetes Association and JDRF.
Medtronic
Sr. Digital Acquisition and Web Manager
Company Name Medtronic
Dates Employed Dec 2012 – Aug 2015
Employment Duration •2 yrs 9 mos
Location Northridge, CA Planned and executed digital marketing acquisition programs supporting all Diabetes product lines, B2C and B2B, as a digital center of excellence. • Led demand generation via inbound marketing tactics such as SEM, SEO, social media, landing page conversion testing, content marketing, online advertising and email • Partnered with agency to design and execute new lead scoring and lead nurturing programs in Marketo to warm up cold leads and escalate active leads to the Sales group • Partnered with agency to diagnose and solve numerous issues in reporting systems • Advocated for the customer journey: as core member of the Digital Center of Excellence team consulted/executed campaigns, urgent customer communications, ad-hoc reporting, and CRM • Led the development of creative including a new corporate brand messaging platform • Recommended workflow enhancements to increase team productivity • Managed and built member lists and campaigns, overseeing system tracking and 800 numbers • Developed lead/sale/shipment forecasts based on goals, insights, learnings and budgets • Formed alliances with major health portals, programmatic/online advertisers • Partnered with a specialized team of agents to handle internet leads, developing a culture of transparency with continual staff development • Developed strategy/executed a new Ambassador program with online profiles that allow prospective customers to search and connect with a current customer for decision support
Created marketing efficiencies, further integrated systems/software, developed and executed best in class marketing campaigns including corporate/marketing websites, SEM, customer loyalty, Facebook, YouTube, mobile, and charitable alliances. Served as the digital SME to the product marketing teams on: product launches, lead generation, social media, marketing automation, innovation, analytics, mobile app development, e-Commerce and CRM.
|
|
|
Post by kc on Jun 5, 2017 14:01:28 GMT -5
Thanks for sharing.. that was really encouraging and chock full of sound bytes! "One month on Afrezza and i have my life back" That's the story that has to develop as users get on Afrezza. Sadly it takes time.
|
|
|
Post by kc on Jun 5, 2017 13:52:53 GMT -5
Listening to the ASM you can hear the passion stated by Damon Dash. I was surprised by how articulate Damon was in getting his message across. He gets the paradigm shift of the product. Now the real question is how to move that message forward.
I can see how Matt might not have been on board with the non-traditional hipster type approach. But marketing Afrezza in the same old manner that all Pharma companies are using is not getting us visibility and we all know this is a product that is having a tough time being scene as doctors are not into change.
Afrezza is a real Paradigm change for treatment. Doctor's don't get it and the don't care to get it as long as their patients are passive and accept what treatment they are receiving. The whole concept of TCOYD is to be an active participant in their own treatment.
I saw that for my very eyes that this weekend at the TCOYD event. One of the sessions I attended was with Dr. Edelman it was titled Patients vs. Providers: Why Are We at Odds About Medications? Steven V. Edelman, MD, and William Polonsky, PhD, CDE in this session you had both patients, Doctors, nurses, it was a full rooms and you can understand why folks are frustrated with their level of treatment. I wish that I took notes or picture of the comments.
There is so much product in the Diabetes market that doctors are confused in what to prescribe. They use all the basic step therapies first and Afrezza is not on their steps. Yet! The TCOYD event showcased all the products. So while we think Afrezza is the Holy Grail for treatment we have to know that the doctors have possibly too many options so they stick to what they are familiar with and easy to prescribe. Dr. Edelman even stated that when talking in the general session about treatment options.
AFREZZA is not for the passive patient who is just doing whatever the DR says. Its for the Patient who is TAKING CONTROL OF THEIR OWN TREATMENT.
We need to attack the problem with visibility in a new manner and the board must have believed that Mike Castagna got it and knows the right direction to move MannKind forward.
The ASM video shows all the keys needed for being scene.
|
|
|
Post by kc on Jun 5, 2017 10:17:37 GMT -5
can you post the link...
|
|
|
Post by kc on Jun 5, 2017 10:17:16 GMT -5
can you post the link...
|
|
|
Post by kc on Jun 5, 2017 10:12:34 GMT -5
KC - awesome update, much thanks! Edelman is also the architect of the Onduo protocol. Did he or anyone mention Onduo and what they are up to? Not specifically mentioning Onduo but his is very engaged about Tech and referred to his CGM multiple times and various other Tech information for staying on top of numbers.
|
|
|
Post by kc on Jun 4, 2017 20:56:58 GMT -5
I really want to know how Dr Edelamn took out a "Technoshpere" from his pocket ......how big were his pockets? "I have validated the effectiveness of the product. I was at the TCOYD event yesterday in Kansas City. I saw how it was receive by diabetics. I personally asked Dr. Steven Edelman about Afrezza and he pulled his Techsphere out of his pocket and said he loved Afrezza and his Partner Dr. Jeremy Pettus did too. During his presentation he presented all diabetes medicines since his group represents the entire spectrum. But his eyes gleamed when talking one on one with me about afrezza." I call it technosphere - perhaps I should have said inhaler. My Bad.
|
|
|
Post by kc on Jun 4, 2017 17:26:51 GMT -5
Correct he works with just about every company who is involved in treating Diabetes. Also does on going CME training for doctors and other healthcare professionals.
|
|
|
Post by kc on Jun 4, 2017 16:49:29 GMT -5
I think you have to attend events like this to get visibility. Is it cost-effective? Nobody really knows. Regarding the 2017 ADA I think they need to be there to show they are a viable organization. I think originally they were thinking about skipping it since most of the attendees are international.
They made a good decision to attend it since their competitors will be there exhibiting their products.
|
|
|
Post by kc on Jun 4, 2017 12:15:36 GMT -5
Dr. Edelman is a thought leader respected by the entire industry. I agree with you. He likes things that make compliance easier for a resisting diabetic who is in denial of needing treatment. The investment of an entire day was well worth it. While the even was going on they also had a CME training event concurrently for DR and HCP who were there. For that activity. Today MannKind is the step child. Hopefully we would grow up and mature nicely.
|
|
|
Post by kc on Jun 4, 2017 10:52:55 GMT -5
Having attended the event on Saturday and staying for the entire event. I have a better view of the entire diabetes market place. I learned that I am a Type 3 diabetic. Yes Type 3. That is a person who knows or worries about a person who is a diabetic.
First and foremost Dr. Steven Edelman and his TCOYD group is the real deal. Meeting him in person and chatting with him you learn about his passion for helping diabetics.
I have validated the effectiveness of the product by attending the TCOYD event yesterday in Kansas City. I saw how it was receive by diabetics. I personally asked Dr. Steven Edelman about Afrezza and he pulled his Techsphere out of his pocket and said he loved Afrezza and his Partner Dr. Jeremy Pettus did too. During his presentation he presented all diabetes medicines since his group represents the entire spectrum. But his eyes gleamed when talking one on one with me about afrezza.
You can see Dr. Edelman believes He was glad to pose with Rich Herrera with both of them holding their Technosphere. He again posed at the MannKind booth.
In the vendor arena I watched folks coming buy the MannKind booth. They were excited. Seems that many of the Type 2 folks didn't even know about Afrezza. Hopefully Mannagement will focus future resources towards type 2. There was a Chef there with a Both and we were chatting about Afrezza and the MannKind rep showed him the On Drop Chrome testing kit and he said Wow! That was exciting and he wanted to go buy one immediately. His view also was that Afrezza will be a winner because of younger people like new technology that Afrezza and One drop brings to the market. There were 4 MannKind representatives there The local KC Rep, one from Omaha and Anthony (Duck Fiabetes) Hightower, Cynthia Rogers-Celt. We should be proud in the way that all four of them represent MannKind. They are passionate about the work they do.
I watched from a distance how the interacted with folks stopping in at the booth and you could watch how attendees were smiling and picking up the sample Inhalers and materials to take home to read.
Rick Herrera was there too. He was telling his story to people who wanted to know about using Afrezza. Rick has been using Afrezza for almost two years. He is a type 2. His A1C continues to drop. Last Thursday evening he was invited to be a guess speaker at a KC area JDRF event where many of the attendees were very appreciative and greatful to hear Rick's Afrezza story.
If TCOYD is in your city take a chance and invest a day to learn more about the entire diabetes market. It will give you a better understanding of the clutter of products on the market and why Endo and HCP are slow to adapt to a new product like Afrezza. I sat in on a couple of sessions. One was about HCP professionals / patients and how they relate or hear each other. It was a very good session that was conducted by Dr. Edelman and Dr. Polansky. One gets the understanding how difficult it is to make changes in a regiment of treatment whether or not its working.
|
|
|
Post by kc on Jun 4, 2017 10:46:40 GMT -5
Kuka hiring Mike was just a great hire. Mean's nothing else. Good people are always looking for a opportunity to put their own stamp on something special. I don't think there is a tie for Mike to Amgen. That being said. There are other things that lead one to believe there is more going on behind the scene. These items are as follows.
1. Deerfied Debt. They now how 5% of the shares and potentially more coming in July. Maybe them or some friendly affiliate that does not need to report have been buying shares with the knowlede in July the convert some more debt to shares. They always seemed to be friendly to Al Mann and may have an agreement monetize Mann Foundation shares in a way to get their value by having a agreement to sell the company for a set value so the trust benefits long term.
2. Strange earnings call early May no questions taken by Matt from Analyists. Maybe there are none following MannKind or they just didn't want to be put in a position to avoid answer some questions that were already rumored in the market. We retail investors are the last to learn they Hedges know how the sausage is ground.
3. Wild trading after that call with one week 73,000,000 shares of 100,000,000 trading hands. On one day 32 million shares. Why? Trading based on rumors that the market knew but we didn't.
4. Shareholders meeting. No Q & A by Matt. Very weird. Don't put yourself out there to answer questions regarding debt and future. The year before questions and comments were about an hour. My guess is the board had already made the decision and told Matt and Mike the plan and didn't want to make the meeting disruptive by so hard questions asked to Matt and then two weeks later Matt was transitioned out.
5. Matt out Mike in. Was this Deerfield saying that as a 5% hold and soon to be bigger holder with additional shares in July to settle debt that we need a more Type A leader and they have confidence in Mike C. I believe that might be the situation. I have said for over 15 months that it was surprising that an Activist investor had not stepped up and take a 10% or more position. I think that might have just happened. Deerfield wanted a quiet peaceful transition and had confidence in Mike moving forward. When MannKind's financing package gets cleaner and the risk of bankruptcy removed we will see the PPS rise. So if Deerfield ends up with another 5% or more then you can guess that they are going to eventually put the company in play. They want a big return for their long term investment in MannKind.
5. Amgen or any other big Pharma. Will we sell out to them? I don't think so at this time. We would welcome their investment and potentially buying a 15% or 20% interest. That is what Al Mann should have done originally. But he didn't as he wanted to sell they 15% or 20% at a higher PPS than they market price at the time of the Sanofi transaction. Did he make a mistake? Probably he did. Look at other Big Pharma deals where the company sold a % and how those deals have done. The easy one is Regeneron. Look at the value of that company today.
So hopefully Our board of Directors / Deerfield/ Mann Trust is positioning MannKind for a Buy In where all parties can benefit from rising share prices as sales develop and distribution channels open up internationally. All three parties have patience to see the plan thru as long as the company has the financing to pull it off.
In conclusion I do think that there is something going on behind the scenes with Deerfield. I hope it benefits the common shareholder like me as I have risked so much invested capital over the years and want to know that the small guy does have a chance to win.
I have validated the effectiveness of the product. I was at the TCOYD event yesterday in Kansas City. I saw how it was receive by diabetics. I personally asked Dr. Steven Edelman about Afrezza and he pulled his Techsphere out of his pocket and said he loved Afrezza and his Partner Dr. Jeremy Pettus did too. During his presentation he presented all diabetes medicines since his group represents the entire spectrum. But his eyes gleamed when talking one on one with me about afrezza.
In the vendor arena I watched folks coming buy the MannKind booth. They were excited. Seems that many of the Type 2 folks didn't even know about Afrezza. Hopefully Mannagement will focus future resources towards type 2. There was a Chef there with a Both and we were chatting about Afrezza and the MannKind rep showed him the On Drop Chrome testing kit and he said Wow! That was exciting and he wanted to go buy one immediately. His view also was that Afrezza will be a winner because of younger people like new technology that Afrezza and One drop brings to the market.
So I guess we just have to wait and see what plays out between know and the end of July......
|
|